Propranolol
| Propranolol | |
|---|---|
| Salts [] | |
|---|---|
| Propranolol hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 259.34 g/mol [1] |
| Melting point | 96 °C [1] |
| Solubility | 61.7 mg/L (at 25 °C) [1] |
| Predicted LogP | 3 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C16H21NO2 |
| IUPAC name | 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol |
| SMILES | CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O |
| InChI | InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3 |
| InChIKey | AQHHHDLHHXJYJD-UHFFFAOYSA-N |
| CAS number | 525-66-6 |
| UNII | 9Y8NXQ24VQ |
| PubChem CID | 4946 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | ~4 hours (range 3–8 hours) |
| Duration of action | Up–12 hours |
| Metabolism | Liver (extensive) CYP1A2, CYP2D6; minor: CYP2C19, CYP3A4; aromatic hydroxylation (mainly 4-hydroxylation), N-dealkylation, side-chain oxidation, glucuronidation |
| Excretion | Urine: 91% |
| Routes of administration | Oral, sublingual, intranasal, rectal, intravenous |
| Dosing[] |
|---|
| Oral [] | |
|---|---|
| Light | ≤ 17.5 mg(1x - 50.0%) |
| Common | 17.5 - 25 mg |
| Strong | 25 - 32.5 mg |
| Heavy | 32.5 - 37 mg |
| Extreme | 37 mg +(1x - 50.0%) |
Statistically derived dosages via DBI-IGS (archived by anodyne.wiki) We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Propranolol (also known as Propanolol, β-Propranolol, βlong, Euprovasin, Proprasylyt, Reducor, Propanalol, Anapriline, propranololo or dl-propranolol) is a substance of the phenol class.
Chemistry
Salts []
Propranolol is typically found in the form of its hydrochloride salt.
Stereochemistry []
Propranolol is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Propranolol matches Lipinski's rule of five.Pharmacology
ATC Classification
- cardiovascular system (C)
- beta blocking agents (C07)
- beta blocking agents (C07A)
- beta blocking agents, non-selective (C07AA)
- (C07AA05)
- propranolol (C07AA05)
MeSH Classification
- adrenergic beta-antagonists (M0000495)
- anti-arrhythmia agents (M0001326)
- antihypertensive agents (M0001456)
- vasodilator agents (M0022559)
Mechanism of action []
Propranolol is a nonselective β-adrenergic receptor antagonist. Blocking of these receptors leads to vasoconstriction, inhibition of angiogenic factors like vascular endothelial growth factor (VEGF) and basic growth factor of fibroblasts (bFGF), induction of apoptosis of endothelial cells, as well as down regulation of the renin-angiotensin-aldosterone system. [1]
Interactions []
Medical side effects []
99 side effects listed on drug labels in SIDER 4.1 (propranolol).
- Sleep disorder
- Bronchitis
- Peripheral coldness
- Agitation
- Dizziness
- Lightheadedness
- Vertigo
- Asthenia
- Fatigue
- Lassitude
- Nightmare
- Irritability
- Decreased appetite
- Somnolence
- Diarrhoea
- Constipation
- Abdominal pain
- Abdominal cramps
- Gastrointestinal pain
- Agranulocytosis
- Alopecia
- Arterial insufficiency
- Mental disorder
- Depression
- Dermatitis exfoliative
- Toxic epidermal necrolysis
- Erythema multiforme
- Stevens-Johnson syndrome
- Dermatitis
- Rash
- Body temperature increased
- Hallucination
- Hypersensitivity
- Laryngospasm
- Systemic lupus erythematosus
- Myopathy
- Myotonia
- Nausea
- Peyronie's disease
- Pharyngitis
- Purpura
- Vascular purpura
- Raynaud's phenomenon
- Urticaria
- Vomiting
- Mood swings
- Affect lability
- Arterial thrombosis
- Colitis ischaemic
- Skin disorder
- Dyspepsia
- Pain
- Rash erythematous
- Paraesthesia
- Erectile dysfunction
- Oropharyngeal discomfort
- Oropharyngeal pain
- Purpura non-thrombocytopenic
- Dry eye
- Anaphylactic shock
- Anaphylactoid reaction
- Abnormal dreams
- Respiratory distress
- Visual impairment
- Amnesia
- Thrombocytopenic purpura
- Insomnia
- Peripheral arterial occlusive disease
- Atrioventricular block
- Block heart
- Bronchospasm
- Bronchiolitis
- Catatonia
- Nervous system disorder
- Infection
- Cough
- Dyspnoea
- Gastrointestinal disorder
- Cardiac arrest
- Cardiac disorder
- Cardiac failure congestive
- Hyperkalaemia
- Hypoglycaemia
- Lethargy
- Neutropenia
- Respiratory tract infection
- Convulsion
- Skin ulcer
- Erythema
- Lower respiratory tract infection
- Disorientation
- Atrioventricular block second degree
- Bradycardia
- Blood glucose decreased
- Feeling cold
- Infestation
- Hypoglycaemic seizure
- Hypersomnia
- Poor quality sleep
Indications
- Angina pectoris
- Arrhythmia
- Arrhythmia supraventricular
- Arteriosclerosis coronary artery
- Atrial fibrillation
- Atrial flutter
- Atrial tachycardia
- Cardiac failure
- Conduction disorder
- Diabetes mellitus
- Diabetic nephropathy
- Digitalis intoxication (NOS)
- Essential tremor
- Familial tremor
- Haemangioma
- Headache
- Hemangioma simplex
- Hyperlipidaemia
- Hypertension
- Hypotension
- Idiopathic hypertrophic subaortic stenosis
- Migraine
- Migraine without aura
- Myocardial depression
- Myocardial infarction
- Neoplasm
- Pain
- Palpitations
- Sinus rhythm
- Supraventricular tachycardia
- Syncope
- Tachyarrhythmia
- Thyrotoxicosis
- Tremor
- Ulcer
- Ventricular arrhythmia
- Ventricular extrasystoles
- Ventricular tachycardia
- Wolff-Parkinson-White syndrome
Subjective effects []
| bonzi / Propranolol [] | |
|---|---|
Experience reports
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4946, Propranolol. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4946
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Propranolol. UNII: 9Y8NXQ24VQ. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/9Y8NXQ24VQ
Inderal (propranolol hydrochloride) Tablets. DailyMed. https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=298083
Inderal LA- propranolol hydrochloride capsule, extended release. DailyMed. 1 August 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35d28979-36b1-4630-b85e-a44e0a443734
Inderal XL- propranolol hydrochloride capsule, extended release. DailyMed. 20 March 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac196ff5-9215-402b-bc57-69aa87f8bade
Hemangeol- propranolol hydrochloride solution. DailyMed. 17 December 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a
Inderal®, Filmdragerad tablett 10 mg. FASS. 1 November 2021. https://fass.se/health/product/19910906000029/fass-text
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | ok | 2026-11-20 06:05:59 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 06:05:55 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 06:05:55 |
| gsrs | ok | 2026-11-20 06:05:56 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0001849) | 2026-11-20 06:05:55 |
| kegg | ok | 2026-11-20 06:05:59 |
| pubchem | ok | 2026-11-20 06:05:54 |
| ok | 2026-11-20 06:05:55 | |
| sider | ok | 2026-11-20 06:05:56 |
| structure | ok | 2026-11-20 06:05:55 |
| wikipedia | ok | 2026-11-20 06:05:56 |